10 results
Primary: To assess the steady-state PK of 450 mg or 600 mg ceritinib taken daily with a low-fat meal as compared with that of 750 mg ceritinib taken daily in the fasted state in patients with metastatic ALK-positive NSCLC.Secondary: Overall response…
1. To evaluate wether ABVS could replace HHUS in women <30 year with focal breast signs2. To evaluate the performance of ABVS in comparison to HHUS in patients with high suspicion of breast cancer3. To start a pilot study to compare ABVS with…
The primary objective of the study is to demonstrate the antitumor activity of LDK378.
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.
The value of implementation and cost-efficacy of Tumor Volume / Breast Volume Ratio, as measured by Automated Breast Volume Scanner (ABVS), during the preoperative workup in breast cancer patients on 1) cosmetic result after BCS, and 2) surgical…
The primary objective is to evaluate the antitumor activity of ceritinib in patients with ALK-positive NSCLC metastatic to the brain and/or toleptomeninges based on whole body overall response rate (ORR), defined as the proportion of patients with a…
The primary objective is to compare the antitumor activity of LDK378 versus reference chemotherapy.The key secondary objective is to compare Overall Survival (OS) in patients treated with LDK378 versus reference chemotherapy (pemetrexed or docetaxel…
Primary: 1. To determine the MTD and/or RDE of the combination ceritinib and nivolumab. 2. To assess the preliminary antitumor activity of the combination.Secondary: 1: To assess the safety profile of the ceritinib and nivolumab combination. 2: To…
To explore the feasibility and opportunities for new imaging procedures, of relevance of Amsterdam UMC prioritized areas, that a ultra-high sensitivity total body PET-CT system can offer for improving diagnosis and dose reduction.The protocol…
The primary objective is to compare the antitumor activity of LDK378 versus reference chemotherapy